

## Drug Monograph

Drug/Drug **Delzicol™ (mesalamine) Delayed-release Capsule /**  
 Class: **aminosalicylate**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Delzicol™ is available in a 400 mg delayed release capsule containing 400 mg of mesalamine.

**Manufacturer:** Warner Chilcott (US), LLC  
Rockaway, NJ 07866

**Indications:** Delzicol™ (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.

**Costs:** \$2.10 per tablet of Delzicol. Wholesale Acquisition Cost

**Summary of Findings:** The Division recommends this product be considered for inclusion in the state specific Preferred Drug List and is currently under solicitation.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Non-Preferred Agent  
 Appropriate Indications  Under Solicitation

Prepared By: Kathleen Wilbers, Pharm.D.  
 Date: May 13, 2013